The partners will work together on a US commercialization strategy for Genetic Technologies' line of existing and future polygenic risk tests.
The test completes a suite of assays designed to detect pathogens that can cause sepsis using the firm's ePlex system.
An early user of a new Mycoplasma genitalium and antibiotic resistance test from SpeeDx that uses the Xpert cartridge shared some initial validation data.
The Chinese joint venture aims to develop infectious disease assays based on iCubate's proprietary amplicon-rescued multiplex PCR technology.
The genetic disease risk test, which covers 59 genes endorsed by ACMG, is offered through the Helix marketplace and includes genetic counseling services.
Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
Individuals identified as needing homozygous FH evaluation will receive confirmatory genetic testing from Invitae and genetic counseling from Genome Medical.
Under the terms of the deal, XCR will develop and implement three assays for NeuMoDx's recently launched 288- and 96-sample molecular systems.
The company envisions creating a "vocometer … to provide disease screening and management solutions based on acoustic analysis of seconds of voice."
The PCR-based Carba assay is designed to detect and differentiate bacterial gene sequences that are associated with resistance to carbapenem antibiotics.
Sophia's STS molecular diagnostic application runs on top of the Sophia AI platform to detect and characterize genomic alterations in solid tumors.
Yikon's test uses next-generation sequencing to screen embryos for chromosomal aneuploidy prior to implantation and does not require a biopsy.
The biological activity sensors in development consist of nanoparticles conjugated with a peptide substrate produce fluorescence in urine associated with immunotherapy response.
The company filed its first suit against Natera in March, claiming the firm's kidney transplant test infringes patents underlying CareDx's AlloSure test.
Evogen's protein biomarker-based test is designed to stratify actively seizing patients from those who have not experienced a recent seizure.
Pharmacogenetics and legal experts took particular issue with the agency's suggestion that "established" drug/gene relationships are found only in FDA-approved drug labels.
As of July 1, the Guardant360 test will be considered medically necessary for aiding therapy selection in advanced lung cancer for health plan members of EviCore.
VALUE-Dx involves six IVD companies and is being heralded by participants as an opportunity for competitors to work together to improve test adoption.